Recurrent or progression of neuroblastoma or neuroblastoma or neuroblastoma refractory to first-line treatment. research hub

Immunotherapy with dinutuximab beta in combination with chemotherapy for the treatment of patients with primary neuroblastoma refractory to standard therapy and with relapsed or progressive disease.

This clinical study tests an immunotherapy drug called dinutuximab beta (Qarziba) combined with chemotherapy. It is for people with neuroblastoma—a rare nerve-tissue cancer—whose cancer has returned, grown, or not responded to usual treatments. The main goal is to see how safe this combination is and monitor side effects.